PMC:7228307 / 37809-38556 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"639","span":{"begin":74,"end":78},"obj":"Gene"},{"id":"640","span":{"begin":443,"end":447},"obj":"Gene"},{"id":"641","span":{"begin":273,"end":277},"obj":"Gene"}],"attributes":[{"id":"A639","pred":"tao:has_database_id","subj":"639","obj":"Gene:2213"},{"id":"A640","pred":"tao:has_database_id","subj":"640","obj":"Gene:2213"},{"id":"A641","pred":"tao:has_database_id","subj":"641","obj":"Gene:2213"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Therapeutic antibody design: improving mAb potency\nMany factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR.\nTherapeutic mAb engineering strategies are directed by many factors including the biology of the target, the nature of the antigen, the desired MOA and possibly the anatomical location of the therapeutic effect,21 and thus to optimize potency for a desired response, the context of use is critical."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T340","span":{"begin":12,"end":20},"obj":"Body_part"},{"id":"T341","span":{"begin":265,"end":268},"obj":"Body_part"},{"id":"T342","span":{"begin":321,"end":326},"obj":"Body_part"}],"attributes":[{"id":"A340","pred":"fma_id","subj":"T340","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A341","pred":"fma_id","subj":"T341","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A342","pred":"fma_id","subj":"T342","obj":"http://purl.org/sig/ont/fma/fma9576"}],"text":"Therapeutic antibody design: improving mAb potency\nMany factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR.\nTherapeutic mAb engineering strategies are directed by many factors including the biology of the target, the nature of the antigen, the desired MOA and possibly the anatomical location of the therapeutic effect,21 and thus to optimize potency for a desired response, the context of use is critical."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T21","span":{"begin":321,"end":326},"obj":"Body_part"}],"attributes":[{"id":"A21","pred":"uberon_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"}],"text":"Therapeutic antibody design: improving mAb potency\nMany factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR.\nTherapeutic mAb engineering strategies are directed by many factors including the biology of the target, the nature of the antigen, the desired MOA and possibly the anatomical location of the therapeutic effect,21 and thus to optimize potency for a desired response, the context of use is critical."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T56","span":{"begin":593,"end":596},"obj":"Disease"}],"attributes":[{"id":"A56","pred":"mondo_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/MONDO_0016702"}],"text":"Therapeutic antibody design: improving mAb potency\nMany factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR.\nTherapeutic mAb engineering strategies are directed by many factors including the biology of the target, the nature of the antigen, the desired MOA and possibly the anatomical location of the therapeutic effect,21 and thus to optimize potency for a desired response, the context of use is critical."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T691","span":{"begin":74,"end":76},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T692","span":{"begin":273,"end":275},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T693","span":{"begin":315,"end":316},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T694","span":{"begin":321,"end":326},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"},{"id":"T695","span":{"begin":443,"end":445},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T696","span":{"begin":696,"end":697},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Therapeutic antibody design: improving mAb potency\nMany factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR.\nTherapeutic mAb engineering strategies are directed by many factors including the biology of the target, the nature of the antigen, the desired MOA and possibly the anatomical location of the therapeutic effect,21 and thus to optimize potency for a desired response, the context of use is critical."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T204","span":{"begin":572,"end":579},"obj":"Chemical"}],"attributes":[{"id":"A204","pred":"chebi_id","subj":"T204","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"}],"text":"Therapeutic antibody design: improving mAb potency\nMany factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR.\nTherapeutic mAb engineering strategies are directed by many factors including the biology of the target, the nature of the antigen, the desired MOA and possibly the anatomical location of the therapeutic effect,21 and thus to optimize potency for a desired response, the context of use is critical."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"639","span":{"begin":74,"end":78},"obj":"Gene"},{"id":"641","span":{"begin":273,"end":277},"obj":"Gene"}],"attributes":[{"id":"A641","pred":"pubann:denotes","subj":"641","obj":"Gene:2213"},{"id":"A639","pred":"pubann:denotes","subj":"639","obj":"Gene:2213"}],"text":"Therapeutic antibody design: improving mAb potency\nMany factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR.\nTherapeutic mAb engineering strategies are directed by many factors including the biology of the target, the nature of the antigen, the desired MOA and possibly the anatomical location of the therapeutic effect,21 and thus to optimize potency for a desired response, the context of use is critical."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T214","span":{"begin":0,"end":50},"obj":"Sentence"},{"id":"T215","span":{"begin":51,"end":141},"obj":"Sentence"},{"id":"T216","span":{"begin":142,"end":448},"obj":"Sentence"},{"id":"T217","span":{"begin":449,"end":747},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Therapeutic antibody design: improving mAb potency\nMany factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR.\nTherapeutic mAb engineering strategies are directed by many factors including the biology of the target, the nature of the antigen, the desired MOA and possibly the anatomical location of the therapeutic effect,21 and thus to optimize potency for a desired response, the context of use is critical."}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T21","span":{"begin":321,"end":326},"obj":"Body_part"}],"attributes":[{"id":"A21","pred":"uberon_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"}],"text":"Therapeutic antibody design: improving mAb potency\nMany factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR.\nTherapeutic mAb engineering strategies are directed by many factors including the biology of the target, the nature of the antigen, the desired MOA and possibly the anatomical location of the therapeutic effect,21 and thus to optimize potency for a desired response, the context of use is critical."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T339","span":{"begin":12,"end":20},"obj":"Body_part"},{"id":"T340","span":{"begin":265,"end":268},"obj":"Body_part"},{"id":"T341","span":{"begin":321,"end":326},"obj":"Body_part"}],"attributes":[{"id":"A341","pred":"fma_id","subj":"T341","obj":"http://purl.org/sig/ont/fma/fma9576"},{"id":"A340","pred":"fma_id","subj":"T340","obj":"http://purl.org/sig/ont/fma/fma62872"},{"id":"A339","pred":"fma_id","subj":"T339","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"Therapeutic antibody design: improving mAb potency\nMany factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR.\nTherapeutic mAb engineering strategies are directed by many factors including the biology of the target, the nature of the antigen, the desired MOA and possibly the anatomical location of the therapeutic effect,21 and thus to optimize potency for a desired response, the context of use is critical."}

{"project":"LitCovid-sentences","denotations":[{"id":"T214","span":{"begin":0,"end":50},"obj":"Sentence"},{"id":"T215","span":{"begin":51,"end":141},"obj":"Sentence"},{"id":"T216","span":{"begin":142,"end":448},"obj":"Sentence"},{"id":"T217","span":{"begin":449,"end":747},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Therapeutic antibody design: improving mAb potency\nMany factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy. The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR.\nTherapeutic mAb engineering strategies are directed by many factors including the biology of the target, the nature of the antigen, the desired MOA and possibly the anatomical location of the therapeutic effect,21 and thus to optimize potency for a desired response, the context of use is critical."}